# Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

> **NCT07398937** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 116 (estimated)

## Conditions studied

- Resectable Stage II-IIIa Squamous NSCLC

## Interventions

- **DRUG:** Serplulimab + chemotherapy
- **DRUG:** Nivolumab + chemotherapy

## Key facts

- **NCT ID:** NCT07398937
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-05
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07398937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07398937, "Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07398937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*